title: [Comparative study of radical prostatectomy versus external beam radiotherapy (75.6 Gy) combined with hormone therapy for prostate cancer of intermediate D'Amico risk classification].
abstract: BACKGROUND
  Thirty-three percent of the localized cancers belongs initially to the group of intermediate risk of D'Amico. The standard treatments validated by the French Association of Urology are the radical prostatectomy and the external beam radiotherapy.
  
  
  OBJECTIVE
  We retrospectively compared the carcinologic results of the radical prostatectomy±adjuvant treatment (RP) and the external beam radiotherapy combining high dose (75.6 Gy) and short hormonotherapy (RH), in the treatment of intermediate risk prostate cancer. The series consisted of 143 patients treated between 2000 and 2006 in the department of Urology and Kidney transplantation of the Conception Hospital, Marseilles. The main assessment criteria was the survival without biological recurrence (SBR).
  
  
  RESULTS
  The median follow-up was 90 months [59-51]. The 5 years and 8 years SBR were 85% and 73% in the RH group, versus 74% and 65% with RP (P=0.196). There was a significant difference between the series: on the age of diagnosis (63.9 versus 73.3 years, P<0.001), the Charlson score of comorbidity (2 versus 3, P<0.001) and the number of intermediate criteria per patients (one intermediate criteria: RP 74% versus 57%, P<0.01).
  
  
  CONCLUSIONS
  According to our study, there was no superiority of the radical prostatectomy±adjuvant treatment or the external radiotherapy combining high dose and concomitant short hormonotherapy on the survival without biological recurrence at 5 and 8 years. Many studies confirm that a concomitant hormonotherapy increases the carcinologic control, even with a high rate external beam radiotherapy.
authors.affiliation: Service d'urologie et transplantation rénale, Aix-Marseille université, hôpital de la Conception, 147, boulevard Baille, 13005 Marseille, France. Electronic address: romainboissier@hotmail.com.
authors.forename: R
authors.initials: R
authors.lastname: Boissier
authors.forename: G
authors.initials: G
authors.lastname: Karsenty
authors.forename: X
authors.initials: X
authors.lastname: Muracciole
authors.forename: L
authors.initials: L
authors.lastname: Daniel
authors.forename: V
authors.initials: V
authors.lastname: Delaporte
authors.forename: C
authors.initials: C
authors.lastname: Maurin
authors.forename: C
authors.initials: C
authors.lastname: Coulange
authors.forename: E
authors.initials: E
authors.lastname: Lechevallier
mesh_terms: D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D015897:Comorbidity; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies
chemical_list: D018931:Antineoplastic Agents, Hormonal; D017430:Prostate-Specific Antigen
keywords: Cancer de prostate; External beam radiotherapy; Hormonothérapie; Intermediate risk; Prostate cancer; Prostatectomie totale; Radical prostatectomy; Radiothérapie externe; Risque intermédiaire; Short hormonotherapy